Cellectar Biosciences INC NEW (CLRB) Dividend History

Company News

• Cellectar Biosciences Announces Compliance Regarding Filing of Form 10-Q

  Cellectar Biosciences, Inc. announced that it has regained compliance with Nasdaq Listing Rule 5250(c)(1) after filing restated financial statements for 2022, 2023, and the first half of 2024.

  GlobeNewswire Inc.
• Cellectar to Restate Previously Issued Financial Statements – Company Announces Receipt of Expected Delinquency Notification Letter from Nasdaq

  Cellectar Biosciences, Inc. announced that it needs to restate its previously issued financial statements due to a review of its accounting treatment for warrants issued in a 2022 financing. The company has received a delinquency notification from Nasdaq and has 60 days to submit a plan to regain compliance.

  GlobeNewswire Inc.
• Cellectar Biosciences to Host Key Opinion Leader Event to Review the Full Results from Its CLOVER WaM Pivotal Trial and Waldenstrom’s Macroglobulinemia Market Landscape

  Event scheduled for Wednesday, July 24, 2024, at 8:00 am EDT Event scheduled for Wednesday, July 24, 2024, at 8:00 am EDT

  GlobeNewswire Inc.
• Cellectar Biosciences and City of Hope Cancer Center Enter Collaboration to Evaluate Iopofosine I 131 in Mycosis Fungoides

  Opportunity for Iopofosine Expansion Within Areas of High Unmet Need in Non-Hodgkin’s Lymphoma

  GlobeNewswire Inc.
• Cellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate Update

  Management to host a conference call today at 8:30 am ET

  GlobeNewswire Inc.